---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-24-000049"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:06:48.075176+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Salarius reports 43% ORR for seclidemstat combo in MDS/CMML at EHA 2024

## Summary
- Seclidemstat + azacitidine: 43% overall response rate (6/14 evaluable) in higher-risk MDS/CMML patients who failed HMA therapy.
- Median overall survival 18.5 months (95% CI 6.1-30.9) vs typical 4-6 months after HMA failure; median event-free survival 7.2 months.
- Phase 1/2 dose-escalation enrolling Cohort 5 (750mg BID) and planned Cohort 6 (900mg BID); MTD not yet reached.
- Dose-limiting toxicity observed in 1 patient at 750mg BID; cohort expanded per protocol; adverse events deemed manageable.
- Data presented by MD Anderson investigator at European Hematology Association meeting June 13-16, 2024.

## SEC filing metadata
- accession: 0001615219-24-000049
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521924000049/0001615219-24-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521924000049/flks-20240617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-24-000049
- JSON: https://secwatch.observer/filing/0001615219-24-000049.json
- Plain text: https://secwatch.observer/filing/0001615219-24-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.